DE69325096T2
(de)
*
|
1992-04-06 |
1999-09-30 |
Biosite Diagnostics Inc., San Diego |
Morphinderivate sowie deren konjugate und labels mit proteinen und polypeptiden
|
US5470997A
(en)
*
|
1992-04-06 |
1995-11-28 |
Biosite Diagnostics Incorporated |
Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels
|
CA2096495C
(en)
*
|
1992-06-16 |
2002-07-09 |
Kathy Palmer Ordonez |
Dual analyte immunoassay
|
US6037455A
(en)
*
|
1992-11-09 |
2000-03-14 |
Biosite Diagnostics Incorporated |
Propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels
|
US5804452A
(en)
*
|
1995-04-27 |
1998-09-08 |
Quidel Corporation |
One step urine creatinine assays
|
US5965375A
(en)
|
1997-04-04 |
1999-10-12 |
Biosite Diagnostics |
Diagnostic tests and kits for Clostridium difficile
|
DE19859912C2
(de)
*
|
1998-12-23 |
2001-06-21 |
Aventis Res & Tech Gmbh & Co |
Testsystem zur Erkennung verschiedener Marker, seine Herstellung sowie Verwendung
|
CA2399202A1
(en)
*
|
2000-03-09 |
2001-09-13 |
Heska Corporation |
Use of recombinant antigens to determine the immune status of an animal
|
US20020110843A1
(en)
*
|
2000-05-12 |
2002-08-15 |
Dumas David P. |
Compositions and methods for epitope mapping
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
US20040126767A1
(en)
*
|
2002-12-27 |
2004-07-01 |
Biosite Incorporated |
Method and system for disease detection using marker combinations
|
US20030199000A1
(en)
*
|
2001-08-20 |
2003-10-23 |
Valkirs Gunars E. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
US7632647B2
(en)
*
|
2001-04-13 |
2009-12-15 |
Biosite Incorporated |
Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
|
US20040203083A1
(en)
*
|
2001-04-13 |
2004-10-14 |
Biosite, Inc. |
Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
|
US20040121350A1
(en)
*
|
2002-12-24 |
2004-06-24 |
Biosite Incorporated |
System and method for identifying a panel of indicators
|
US20040253637A1
(en)
*
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
US7713705B2
(en)
*
|
2002-12-24 |
2010-05-11 |
Biosite, Inc. |
Markers for differential diagnosis and methods of use thereof
|
US20030219734A1
(en)
*
|
2001-04-13 |
2003-11-27 |
Biosite Incorporated |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
US7524635B2
(en)
*
|
2003-04-17 |
2009-04-28 |
Biosite Incorporated |
Methods and compositions for measuring natriuretic peptides and uses thereof
|
ATE458199T1
(de)
|
2001-05-04 |
2010-03-15 |
Biosite Inc |
Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
|
DE10125258A1
(de)
|
2001-05-23 |
2003-01-09 |
November Ag Molekulare Medizin |
Verfahren zur Bestimmung des Bindeverhaltens von an Ziel-Molekülen spezifisch bindenden Liganden
|
JP2005522669A
(ja)
*
|
2001-08-20 |
2005-07-28 |
バイオサイト インコーポレイテッド |
卒中および脳損傷の診断マーカーおよびその使用方法
|
US6780602B2
(en)
*
|
2001-11-01 |
2004-08-24 |
Microbiosystems, Limited Partnership |
Taxonomic identification of pathogenic microorganisms and their toxic proteins
|
US7459127B2
(en)
|
2002-02-26 |
2008-12-02 |
Siemens Healthcare Diagnostics Inc. |
Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces
|
US7094354B2
(en)
|
2002-12-19 |
2006-08-22 |
Bayer Healthcare Llc |
Method and apparatus for separation of particles in a microfluidic device
|
US7125711B2
(en)
|
2002-12-19 |
2006-10-24 |
Bayer Healthcare Llc |
Method and apparatus for splitting of specimens into multiple channels of a microfluidic device
|
CA2522709A1
(en)
|
2003-04-17 |
2004-11-04 |
Ciphergen Biosystems, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
US7435381B2
(en)
|
2003-05-29 |
2008-10-14 |
Siemens Healthcare Diagnostics Inc. |
Packaging of microfluidic devices
|
US20040265171A1
(en)
*
|
2003-06-27 |
2004-12-30 |
Pugia Michael J. |
Method for uniform application of fluid into a reactive reagent area
|
US7347617B2
(en)
|
2003-08-19 |
2008-03-25 |
Siemens Healthcare Diagnostics Inc. |
Mixing in microfluidic devices
|
WO2005033327A2
(en)
*
|
2003-09-29 |
2005-04-14 |
Biosite Incorporated |
Methods and compositions for the diagnosis of sepsis
|
US6991911B2
(en)
*
|
2003-12-15 |
2006-01-31 |
Dade Behring Inc. |
Assay for entactogens
|
US20050130243A1
(en)
*
|
2003-12-15 |
2005-06-16 |
Zheng Yi F. |
Assay for entactogens
|
US7022492B2
(en)
*
|
2003-12-15 |
2006-04-04 |
Dade Behring Inc. |
Ecstasy haptens and immunogens
|
US7115383B2
(en)
*
|
2004-03-22 |
2006-10-03 |
Dade Behring Inc. |
Assays for amphetamine and methamphetamine
|
US7037669B2
(en)
*
|
2004-03-22 |
2006-05-02 |
Dade Behring Inc. |
Assays for amphetamine and methamphetamine using stereospecific reagents
|
US20060051825A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Buechler Kenneth F |
Methods and compositions for measuring canine BNP and uses thereof
|
US20080050832A1
(en)
*
|
2004-12-23 |
2008-02-28 |
Buechler Kenneth F |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
WO2006078813A2
(en)
*
|
2005-01-21 |
2006-07-27 |
Biosite Incorporated |
Arginine analogs, and methods for their synthesis and use
|
US7939342B2
(en)
|
2005-03-30 |
2011-05-10 |
Kimberly-Clark Worldwide, Inc. |
Diagnostic test kits employing an internal calibration system
|
DE502005002994D1
(de)
*
|
2005-04-04 |
2008-04-10 |
Micronas Holding Gmbh |
Verfahren und Vorrichtung zum Bestimmen der Konzentrationen von mindestens zwei Liganden
|
US20070087453A1
(en)
*
|
2005-10-19 |
2007-04-19 |
Council Of Scientific And Industrial Research |
Immuno conjugate and process for preparation thereof
|
US20070218498A1
(en)
*
|
2005-08-30 |
2007-09-20 |
Buechler Kenneth F |
Use of soluble FLT-1 and its fragments in cardiovascular conditions
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
EP2005168A4
(de)
*
|
2006-03-09 |
2009-05-20 |
Biosite Inc |
Verfahren und zusammensetzung zur diagnose von krankheiten der aorta
|
EP1845377A1
(de)
|
2006-04-10 |
2007-10-17 |
Micronas GmbH |
Verfahren und Vorrichtung zum Bestimmen der Konzentrationen von Liganden
|
US20080118924A1
(en)
*
|
2006-05-26 |
2008-05-22 |
Buechler Kenneth F |
Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
AU2007255981A1
(en)
|
2006-06-07 |
2007-12-13 |
Otago Innovation Limited |
Diagnostic methods and markers
|
WO2008094198A2
(en)
*
|
2006-07-28 |
2008-08-07 |
Biosite Incorporated |
Devices and methods for performing receptor binding assays using magnetic particles
|
CA2662629C
(en)
|
2006-09-07 |
2019-08-13 |
University Of Otago |
Bnp signal peptide fragments for acute cardiac disorders
|
DE502006005987D1
(de)
*
|
2006-10-20 |
2010-03-11 |
Micronas Holding Gmbh |
Verfahren und Vorrichtung zum Bestimmen der Konzentrationen von Liganden
|
US8524462B2
(en)
*
|
2006-11-14 |
2013-09-03 |
Alere San Diego, Inc. |
Methods and compositions for diagnosis and prognosis of renal artery stenosis
|
WO2008060607A2
(en)
|
2006-11-14 |
2008-05-22 |
Biosite Incorporated |
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
|
US8221995B2
(en)
*
|
2007-03-23 |
2012-07-17 |
Seok-Won Lee |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
US20090004755A1
(en)
*
|
2007-03-23 |
2009-01-01 |
Biosite, Incorporated |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
US20090053832A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Link William F |
Simultaneous assay for determining drugs
|
US7947465B2
(en)
*
|
2007-08-20 |
2011-05-24 |
Bio-Rad Laboratories, Inc. |
Simultaneous assay for determining drugs
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
AU2009224114B2
(en)
|
2008-03-12 |
2013-02-21 |
Otago Innovation Limited |
Biomarkers
|
WO2009113879A1
(en)
|
2008-03-12 |
2009-09-17 |
Christopher Joseph Pemberton |
Biomarkers
|
AU2009285550B2
(en)
|
2008-08-28 |
2015-06-18 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2735590A1
(en)
|
2008-08-29 |
2010-03-04 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US20110207161A1
(en)
|
2008-10-21 |
2011-08-25 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CN102246035B
(zh)
|
2008-10-21 |
2014-10-22 |
阿斯图特医药公司 |
用于诊断和预后肾损伤和肾衰竭的方法和组合物
|
EP2361018B1
(de)
|
2008-11-10 |
2015-04-01 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen für die diagnose und prognose von nierenschädigung und nierenversagen
|
CA2743253A1
(en)
|
2008-11-22 |
2010-05-27 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2010065944A1
(en)
*
|
2008-12-05 |
2010-06-10 |
Serametrix |
Autoantibody detection systems and methods
|
NZ594772A
(en)
|
2009-02-06 |
2013-05-31 |
Astute Medical Inc |
Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
|
CA2751435A1
(en)
|
2009-02-06 |
2010-08-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and failure
|
US9752191B2
(en)
|
2009-07-09 |
2017-09-05 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
EP2462446B1
(de)
|
2009-08-07 |
2017-09-27 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
|
BR112012002711A2
(pt)
|
2009-08-07 |
2016-11-01 |
Astute Medical Inc |
metodo para avaliar o estado renal em um individuo, e, medicao de proteina
|
AU2010286559B2
(en)
|
2009-08-28 |
2015-01-22 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2011035097A1
(en)
|
2009-09-18 |
2011-03-24 |
Astute Medical, Inc. |
Methods and composition for diagnosis and prognosis of renal injury and renal failure
|
NZ599105A
(en)
|
2009-09-21 |
2014-08-29 |
Astute Medical Inc |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
JP2013510322A
(ja)
|
2009-11-07 |
2013-03-21 |
アスチュート メディカル,インコーポレイテッド |
腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
|
JP2013510321A
(ja)
|
2009-11-07 |
2013-03-21 |
アスチュート メディカル,インコーポレイテッド |
腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
KR20120123056A
(ko)
|
2009-12-20 |
2012-11-07 |
아스튜트 메디컬 인코포레이티드 |
신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
|
NZ601648A
(en)
|
2010-02-05 |
2015-05-29 |
Astute Medical Inc |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
AU2011213685B2
(en)
|
2010-02-05 |
2014-10-30 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
HUE029304T2
(en)
|
2010-02-05 |
2017-02-28 |
Astute Medical Inc |
Procedures and Preparations for Diagnosing and Predicting Kidney Damage and Kidney Failure
|
EP3070474A3
(de)
|
2010-02-26 |
2016-12-07 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
WO2011129382A1
(en)
|
2010-04-16 |
2011-10-20 |
Abbott Japan Co. Ltd. |
Methods and reagents for diagnosing rheumatoid arthritis
|
IN2012MN02812A
(de)
|
2010-06-23 |
2015-05-22 |
Astute Medical Inc |
|
EP3339860A1
(de)
|
2010-06-23 |
2018-06-27 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
CN103080743B
(zh)
|
2010-06-23 |
2015-07-22 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断及预后的方法和组合物
|
NZ605640A
(en)
|
2010-07-19 |
2016-01-29 |
Otago Innovation Ltd |
Signal biomarkers
|
US10557856B2
(en)
|
2010-09-24 |
2020-02-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Biomarkers of renal injury
|
CN103189394B
(zh)
|
2010-09-24 |
2016-08-17 |
阿斯图特医药公司 |
利用透明质酸评价肾损伤的方法和组合物
|
US20130316370A1
(en)
|
2010-10-07 |
2013-11-28 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP2646822B1
(de)
|
2010-11-29 |
2017-11-01 |
Alere San Diego, Inc. |
Verfahren zur diagnose und risikovorhersage bei herzversagen
|
US20140147864A1
(en)
|
2011-01-08 |
2014-05-29 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP3761034A3
(de)
|
2011-01-26 |
2021-02-17 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Urinbiomarker zur vorhersage der erholung nach einer akuten nierenverletzung: proteomik
|
US20130330752A1
(en)
|
2011-01-29 |
2013-12-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
PL2748605T4
(pl)
|
2011-08-26 |
2019-08-30 |
Astute Medical, Inc. |
Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia nerek i niewydolności nerek
|
EP3282257A1
(de)
|
2011-11-22 |
2018-02-14 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
|
US10935548B2
(en)
|
2011-12-08 |
2021-03-02 |
Astute Medical, Inc. |
Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
|
EP2791173B1
(de)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
MY194587A
(en)
|
2012-01-27 |
2022-12-05 |
Abbvie Inc |
Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
|
AU2013226184A1
(en)
|
2012-02-27 |
2014-09-18 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
BR112014018717A8
(pt)
|
2012-03-13 |
2017-07-11 |
Abbvie Inc |
Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b
|
EP2828282B1
(de)
|
2012-03-20 |
2017-12-27 |
Otago Innovation Limited |
Biomarker
|
WO2013152047A1
(en)
|
2012-04-02 |
2013-10-10 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of sepsis
|
US9733261B2
(en)
|
2012-04-24 |
2017-08-15 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
|
EP2875347B1
(de)
|
2012-07-23 |
2019-05-08 |
Astute Medical, Inc. |
Verfahren zur diagnose von sepsis
|
EP2882767B1
(de)
|
2012-08-11 |
2023-07-12 |
Astute Medical, Inc. |
Bewertung von nierenläsionen mithilfe von hyaluronsäure
|
CN105074466B
(zh)
|
2013-01-17 |
2018-01-09 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断及预后的方法和组合物
|
AU2014239248B2
(en)
|
2013-03-14 |
2017-02-23 |
Alere San Diego, Inc. |
6-Acetylmorphine analogs, and methods for their synthesis and use
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
CN105556305A
(zh)
|
2013-06-05 |
2016-05-04 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断及预后的方法和组合物
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
CA2920521A1
(en)
|
2013-08-07 |
2015-02-12 |
Astute Medical, Inc. |
Assays for timp2 having improved performance in biological samples
|
TWI716341B
(zh)
|
2013-08-23 |
2021-01-21 |
美商瑞塔醫藥有限責任公司 |
使用齊墩果酸(bardoxolone methyl)或其類似物治療和預防內皮功能障礙之方法
|
WO2015031626A1
(en)
|
2013-08-28 |
2015-03-05 |
Abbvie Inc. |
Soluble cmet assay
|
WO2015179773A1
(en)
|
2014-05-22 |
2015-11-26 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
US10794917B2
(en)
|
2013-09-20 |
2020-10-06 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
|
EP3556863A1
(de)
|
2013-11-06 |
2019-10-23 |
Astute Medical, Inc. |
Tests auf igfbp7 mit verbesserter leistung bei biologischen proben
|
WO2015084939A1
(en)
|
2013-12-03 |
2015-06-11 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US10711311B2
(en)
|
2013-12-30 |
2020-07-14 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Genomic rearrangements associated with prostate cancer and methods of using the same
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
EP3146455A4
(de)
|
2014-05-22 |
2018-05-02 |
The Scripps Research Institute |
Molekulare signaturen zur unterscheidung von lebertransplantatabstossungen oder -verletzungen
|
EP3146076A4
(de)
|
2014-05-22 |
2018-05-09 |
The Scripps Research Institute |
Mit subklinischer nierentransplantatabstossung assoziierte genexpressionsprofile
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
KR102431003B1
(ko)
|
2014-10-20 |
2022-08-09 |
아스튜트 메디컬 인코포레이티드 |
신손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
|
ES2943579T3
(es)
|
2014-12-18 |
2023-06-14 |
Astute Medical Inc |
Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
|
US11243202B2
(en)
|
2015-04-09 |
2022-02-08 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US11143658B2
(en)
|
2015-05-12 |
2021-10-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
JP2018518676A
(ja)
|
2015-06-11 |
2018-07-12 |
アスチュート メディカル,インコーポレイテッド |
腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
|
US20180224466A1
(en)
|
2015-06-17 |
2018-08-09 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
|
JP2018523469A
(ja)
|
2015-07-10 |
2018-08-23 |
ウエストバージニア ユニバーシティWest Virginia University |
脳卒中および脳卒中重篤度のマーカー
|
EP3359558B1
(de)
|
2015-10-06 |
2023-12-13 |
Bio-Rad Laboratories, Inc. |
Immunoassays für borrelia und materialien dafür
|
US11192857B2
(en)
|
2016-05-18 |
2021-12-07 |
Alere San Diego, Inc. |
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
|
AU2017277305A1
(en)
|
2016-06-06 |
2018-12-20 |
Astute Medical, Inc. |
Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
AU2017339858B2
(en)
|
2016-10-03 |
2022-02-17 |
Abbott Laboratories |
Improved methods of assessing GFAP status in patient samples
|
US11633411B2
(en)
|
2016-10-04 |
2023-04-25 |
University Of Maryland, Baltimore |
Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
|
NZ753546A
(en)
|
2016-11-08 |
2022-10-28 |
Reata Pharmaceuticals Holdings Llc |
Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
|
EP3568695A4
(de)
|
2017-01-12 |
2020-12-16 |
Astute Medical, Inc. |
Verfahren und zusammensetzungen zur bewertung und behandlung von nierenschäden und nierenversagen auf basis von c-c-motiv-chemokinligand-14-messung
|
CN110678751A
(zh)
|
2017-03-09 |
2020-01-10 |
克利拉生物技术有限公司 |
针对细胞衰老的生物标志物
|
JP7346300B2
(ja)
|
2017-03-23 |
2023-09-19 |
アボット・ラボラトリーズ |
早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
|
US10877048B2
(en)
|
2017-04-15 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
WO2018200823A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
CN110753700A
(zh)
|
2017-05-07 |
2020-02-04 |
机敏医药股份有限公司 |
胰岛素样生长因子结合蛋白7和金属蛋白酶2组织抑制物在肾脏替代疗法的管理中的用途
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
EP3631467A1
(de)
|
2017-05-30 |
2020-04-08 |
Abbott Laboratories |
Verfahren zur hilfe bei der diagnose und evaluierung einer leichten traumatischen hirnläsion bei einer person unter verwendung von herztroponin i
|
CA3068041C
(en)
|
2017-07-03 |
2024-06-25 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
EP3721234A1
(de)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
|
CA3067057A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
EP3732196A4
(de)
|
2017-12-28 |
2022-01-05 |
Astute Medical, Inc. |
Antikörper und assays für ccl14
|
CN111699391A
(zh)
|
2017-12-29 |
2020-09-22 |
雅培实验室 |
用于诊断和评估创伤性脑损伤的新型生物标志物和方法
|
EP3788377A1
(de)
|
2018-05-04 |
2021-03-10 |
Abbott Laboratories |
Hbv-diagnostische, prognostische und therapeutische verfahren und produkte
|
WO2020051231A1
(en)
|
2018-09-04 |
2020-03-12 |
H. Lee Moffitt Cancer Center & Research Institute Inc. |
Use of delta-tocotrienol for treating cancer
|
EP4375669A3
(de)
|
2018-12-28 |
2024-07-24 |
Abbott Laboratories |
Direkter nachweis von einzelmolekülen auf mikropartikeln
|
WO2020144535A1
(en)
|
2019-01-08 |
2020-07-16 |
Aduro Biotech Holdings, Europe B.V. |
Methods and compositions for treatment of multiple myeloma
|
WO2020180695A1
(en)
|
2019-03-01 |
2020-09-10 |
Abbott Laboratories |
Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
|
EP4136459A1
(de)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
|
US20230255982A1
(en)
|
2020-05-09 |
2023-08-17 |
Reata Pharmaceuticals Holdings, LLC |
Methods of treating covid-19 using bardoxolone methyl or analogs thereof
|
US20230236205A1
(en)
|
2020-06-01 |
2023-07-27 |
Loop Diagnostics, S.L. |
Method and kit for the early detection of sepsis
|
JP2023536737A
(ja)
|
2020-08-04 |
2023-08-29 |
アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー |
Sars-cov-2を検出するためのアッセイ
|
US20220043000A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Methods and kits for detecting sars-cov-2 protein in a sample
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022126129A1
(en)
|
2020-12-11 |
2022-06-16 |
Reata Pharmaceuticals, Inc. |
Synthetic triterpenoids for use in therapy
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
CA3216320A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
US20240118279A1
(en)
|
2021-06-14 |
2024-04-11 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
EP4392783A1
(de)
|
2021-08-27 |
2024-07-03 |
Abbott Laboratories |
Verfahren zum nachweis von immunoglobulin g, subklassen 4 (igg4) in einer biologischen probe
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022413677A1
(en)
|
2021-12-17 |
2024-06-27 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
AU2022423989A1
(en)
|
2021-12-28 |
2024-07-04 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024059692A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|